Cancer-Associated Thrombosis

Slides:



Advertisements
Similar presentations
Addressing the Challenges in Primary and Secondary Stroke Prevention
Advertisements

Covering the Bases in Cardioversion
Anticoagulant Safety Remains a Problem Emergency Hospitalizations for Adverse Drug Events.
NOACs for Cancer-Associated Thrombosis:
Anticoagulants in Interventional Cardiology:
Managing Bleeds in Patients Anticoagulated With Warfarin and Other Agents.
NOACs In Long-term VTE Treatment: A State Of The Art Review
US Guidelines US Guidelines Low-risk Patients.
NOACs, AF, and PCI: What Do the Latest Data Suggest?
Barriers to Oral Anticoagulant Use for Stroke Prevention in AF
Thrombosis, Cancer, and NOACs
Access to NOAC Therapy:
NOACs in Clinical Practice: Are They All the Same?
Introduction ESC Annual Meeting in Review: NOACs and NVAF: Real-World Data, Guidelines, and More.
Emergency Management of NOAC Bleeding
Advances in Coronary Artery Disease: Moving Beyond Antiplatelet Therapy.
Anticoagulation Highlights From the American Heart Association Meeting 2017.
Clinical Presentations of VTEa,b NOACs VTE Acute Treatment Trials.
Before and After: Patient Cases in Onychomycosis
Oral Anticoagulants in AFa,b A Brief History.
Global Burden of VTE. Preventing Thrombosis During and Post-Hospitalization: New Paradigms in Clinical Care.
Surveying the Safety of NOACs in the Real World
Selecting NOACs for High-Risk Patients
A Case Challenge: Anticoagulant Choices for Acute PE
NOAC Use in AF: REAL-WORLD Studies WITH REAL RESULTS
Assessing the Risk for Stroke in Patients With Atrial Fibrillation
Are We Closer to Personalized Medicine in MS?
New Oral Anticoagulants and VTE Management
VTE Treatment Conventional Approach
Access to NOAC Therapy:
Antithrombotic Protection in CAD and HF
TAVR and the Risk of Thrombosis
Adherence in SPAF: Measures to Improve Care
What Anticoagulant Registries Are Revealing
Learning Objectives Classification of VTE Goals of VTE Treatment.
A Better Solution For Cancer Patients With VTE?
VTE in Cancer.
Reversal Strategies for VKA: Truths and Misconceptions
Forest plot of the HRs for DOACs vs warfarin for (A) new or recurrent VTE and (B) major bleeding based on the published subanalyses of the patients with.
Real-World Evidence in VTE
Dos and Don’ts for High-Risk Elderly Patients With AF
Extending Treatment for Thrombosis: What’s the Right Choice?
Practical Considerations to Extend Treatment for VTE
Extraordinary Cases of VTE Prevention in Patients With Cancer
Treatment of Thromboembolic Disease The Need for Multiple Perspectives
Anticoagulation and Thrombosis Management
Trials and Tribulations in VTE: How Do Real-World Data Fit In?
Long-Term Treatment of VTE: Case Studies
Factor Xa Inhibitors in PAD
A Time for Change for Managing Patients With VTE Who Have Cancer
Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?
Managing Pulmonary Embolism Posthospital Discharge
NOAC Studies in VTE AF Studies Superior Outcomes.
Extraordinary Cases in VTE
How I treat cancer-associated venous thromboembolism
Program Goals Background: Anticoagulation in Patients With VTE.
Improving Adherence to Antiplatelet Therapy After an ACS Event
Treatment and secondary prevention strategy diagram for VTE in patients with active cancer based on the treatment guidelines for cancer-associated VTE.
Incidence of (A) recurrent VTE and (B) major bleeding in select randomised clinical trials of LMWH for the treatment and secondary prevention of VTE in.
An Unmet Need.
Disease Burden of VTE Phases of VTE Treatment.
5 Good Minutes on Atrial Fibrillation-related Stroke
At the Crossroads of Coagulation
VKA Reversal and LVADs.
VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.
Treatment algorithm. Treatment algorithm. (A) Suggested treatment algorithm for symptomatic and incidental DVT or PE in cancer patients. (B) Suggested.
Extraordinary Cases in Stroke Prevention
Antithrombotic Therapy in AF Patients Undergoing PCI
What's New in NOACs in AF?.
Treating Pulmonary Embolism Today
Presentation transcript:

Cancer-Associated Thrombosis

Cancer-Associated Thrombosis Who Is at Risk?

Cancer-Associated Thrombosis How to Identify Those at Risk

Risk of VTE in Medical Patients

Primary Prevention Trials

Bleeding Risk in Patients With Cancer

Treating the Patient With VTE

How Long to Treat?

NOACs vs LMWH in Patients With Cancer

Study Results

LMWH and VKAs

Study Results (cont)

Patient Persistence With Anticoagulation LMWH vs Oral Agents

Challenges of Anticoagulation Therapy

Ottawa Risk Score

Tailoring Treatment

ISTH Guidance Statement

CARAVAGGIO

Managing Anticoagulation

Managing Anticoagulation (cont)

Summary

Abbreviations

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.